BioAlliance Expands LoramycTM Franchise by Signing a South East Asia Deal Worth up to $12M
Published: Mar 31, 2008
BioAlliance Pharma’s third commercial partnership is potentially worth $12 million to the Paris-based firm, including $1.5 million on signature and a further $1.5 million on first sale in Korea - the remainder being sales milestones (up to $9 million) in the designated territory and double-digit royalties commensurate with the product stage.
Please, find below the English and French press releases, which are also available in PDF by clicking on the links at the end of this email.
Caroline Carmagnol ALIZE RP Tel.: +33 6 64 18 99 59 Hcaroline@alizerp.com